LP-182 Pharmacokinetics, selectivity profile, and exposure-response relationship for efficacy and safety in a phase 2 study of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with systemic lupus erythematosus

• Bindu Murthy,
• Qihong Zhao,
• Takafumi Ide,
• Manoj Chiney,
• Huynh Yen Thanh Bach,
• Vineet Goti,
• Coburn Hobar,
• Urvi Aras

Affiliations

Bindu Murthy

14Bristol-Myers Squibb, Princeton, New Jersey, USA

Qihong Zhao

Oncology Discovery Biology, Bristol Myers Squibb, Lawrenceville, New Jersey, USA

Takafumi Ide

1Clinical Pharmacology, Bristol Myers Squibb, USA

Manoj Chiney

1Clinical Pharmacology, Bristol Myers Squibb, USA

Huynh Yen Thanh Bach

1Clinical Pharmacology, Bristol Myers Squibb, USA

Vineet Goti

1Clinical Pharmacology, Bristol Myers Squibb, USA

Coburn Hobar

2Clinical Development, Bristol Myers Squibb, USA

Urvi Aras

1Clinical Pharmacology, Bristol Myers Squibb, USA